Ratiopharm, a prominent brand under the Teva umbrella, emphasizes the development and provision of high-quality generic medications and innovative health solutions. The company offers a diverse product range, including pain relief medications like Synofen, which combines Paracetamol and Ibuprofen to deliver a threefold effect: rapid onset, strong efficacy, and good tolerability. This combination allows for effective pain management while minimizing side effects, making it suitable for treating various types of pain, such as headaches, backaches, and joint pain. Ratiopharm's commitment to quality is reflected in its extensive product offerings, which cover nearly all therapeutic areas and are regularly updated with new, valuable preparations.

In addition to its pharmaceutical products, Ratiopharm is dedicated to sustainability and social responsibility. The company operates under high environmental standards and engages in eco-friendly production and logistics practices. Ratiopharm also supports various social, cultural, and sports initiatives, demonstrating its commitment to community well-being. The brand's focus on transparency and communication with patients and healthcare professionals further underscores its dedication to providing safe and effective healthcare solutions. Overall, Ratiopharm combines quality, sustainability, and social engagement to enhance health outcomes for individuals and communities alike.

Germany

About ratiopharm
ratiopharm became known as the first generics company in Europe. Today, ratiopharm is a pharmaceutical brand with a broad portfolio of OTC and generic prescription medicines in several European countries. Including Germany, Austria, Spain and Finland.

ratiopharm - a brand of Teva
Since 2010, ratiopharm has been part of Teva Pharmaceuticals, a global leader in generics and biopharmaceuticals. As part of Teva, we benefit from access to innovative networks and high-quality, internally produced active ingredients.

Access to medicines and health
Every day, we work to ensure access to medicines and thus the supply of essential medicines to millions of people. We provide high-quality generics for nearly all indications and therapeutic solutions that are customized to the needs of our patients. We are convinced that quality can be offered at fair prices. And that not only helps individuals, but also makes a sustainable contribution to the performance and efficiency of the healthcare system.

Ratiopharm (Teva)

Dyskinesia

Huntington's disease

AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.

AUSTEDO® XR (deutetrabenazine) 

Crohns disease

Ulcerative colitis

SELARSDI is a monoclonal antibody and a biosimilar to Stelara® (ustekinumab). Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.2 The biosimilar has been launched in Canada as JAMTEKI, in Europe as UZPRUVO and in Japan as USTEKINUMAB BS (F). It has been approved in the U.S. as SELARSDI. Applications are also under review in multiple countries globally.

SELARSDI™ (ustekinumab-aekn)

Mental health

Schizophrenia

UZEDY (risperidone) extended-release injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults. In clinical trials, UZEDY significantly reduced the risk of schizophrenia relapse.1,8 UZEDY administers risperidone through SteadyTeq™ copolymer technology under license from MedinCell that allows for absorption and sustained release after subcutaneous injection. UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals.

UZEDY (risperidone)

Migraines

AJOVY® (fremanezumab)

Osteoporosis

About TVB-009P (denosumab) 
TVB-009P is a monoclonal antibody and a biosimilar candidate to Prolia® (denosumab). Denosumab targets RANKL (receptor activator of nuclear factor kappa-B ligand), a key protein involved in the regulation of bone metabolism and osteoclast formation. TVB-009P is an investigational product and has not received regulatory approval in any country.

TVB-009P (denosumab) (Prolia Biosimilar)

Bipolar I Disorder

UZEDY

TEV-‘749 is an investigational once-monthly subcutaneous long-acting injection of the 2nd generation antipsychotic olanzapine and is not approved by any regulatory authority for any use and its safety and efficacy are not established.

Ratiopharm (Teva)

Company Details